Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

NCT06856278 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Throid Carcinoma

Interventions

DRUG: NKG2D CAR-NK with PD-1 Antibody

Sponsor

Zhejiang Provincial People's Hospital